Trial reportClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis2018
Time in the Therapeutic Range for Assessing Anticoagulation Quality in Patients Receiving Continuous Unfractionated Heparin.
Trial report in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Influence of intrapatient variability in tacrolimus trough levels on acute rejection in pediatric kidney transplant recipients.Pediatric nephrology (Berlin, Germany) · 2026Article
- Impact of time in therapeutic range (TTR) within the first 72 h on prognosis in patients with pulmonary embolism treated with unfractionated heparin.Journal of thrombosis and thrombolysis · 2026Article
- Analysis of aPTT predictors after unfractionated heparin administration in intensive care units using machine learning models.PloS one · 2025Article
- Time in Therapeutic Range of Unfractionated Heparin-Based Therapy in Critically Ill Patients with COVID-19 Pneumonia.Therapeutics and clinical risk management · 2024Article
- Therapeutic inefficacy of protocol driven intravenous unfractionated heparin infusion in the current era.American heart journal plus : cardiology research and practice · 2023Article
- Comparison of Time Within Therapeutic Range Using Anti-Factor Xa Versus Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin in Children.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2023Article
- Predicting Therapeutic Response to Unfractionated Heparin Therapy: Machine Learning Approach.Interactive journal of medical research · 2022Article
- Impact of Protocolized Pharmacist Intervention on Critical Activated Partial Thromboplastin Time Values With Heparin Infusions.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2021Article
- Development of Multidisciplinary Anticoagulation Management Guidelines for Patients Receiving Durable Mechanical Circulatory Support.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
- Outcomes Associated with Time in Therapeutic Range for Patients Receiving Intravenous Unfractionated Heparin.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to variable pharmacokinetic properties, therapeutic anticoagulation with continuous unfractionated heparin (UFH) requires ongoing laboratory monitoring, generally with activated partial thromboplastin time (aPTT). In the ambulatory setting, clinicians who manage warfarin therapy often use time in the therapeutic range (TTR) to estimate a percentage of time the international normalized ratio is therapeutic. We applied the TTR concept to aPTT monitoring for therapeutic UFH and used 2 methodologies for estimation: percentage of aPTT values in range (%aIR) and a modification of the Rosendaal method (mod-Rosendaal). This study included adult inpatients admitted between September 30, 2015, and September 30, 2016, at Brigham and Women's Hospital. For each patient, all available aPTT values were extracted to calculate 2 individual TTRs according to each methodology. Comparison between methods was performed using Student
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.